Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Safety and efficacy of taurine as an add-on treatment for tics in youngsters.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur. J. Neurol. Subsets: In Process; MEDLINE
    • Publication Information:
      Publication: <2014- > : Oxford : Wiley
      Original Publication: Oxford ; New York : Rapid Communications, [1994-
    • Abstract:
      Background and Purpose: The pathophysiological model of tics generally describes disruption of γ-aminobutyric acid transmission, and taurine is found to be an agonist of γ-aminobutyric acid receptors. The study aimed to evaluate the safety and efficacy of taurine as an add-on treatment for tics.
      Methods: Four hundred and four youngsters with tic disorders were randomly assigned to 12 weeks of either oral taurine or placebo. The Yale Global Tic Severity Scale was used to measure tic severity. The primary outcome measure was global severity scores reduced by more than 60% compared with baseline scores.
      Results: Three hundred and eighty-two patients were successfully treated. At week 4, no significant differences were found in the treatment effect and the total occurrence of adverse drug reactions between the taurine and placebo groups. At week 12, the proportion of significant improvement in tics was significantly higher in the taurine group than the placebo group (53.4% with taurine versus 34.5% without taurine; relative risk 1.546; P < 0.001), and no group differences were found in the total occurrence of adverse drug reactions.
      Conclusions: Taurine is safe and effective for tics.
      (© 2019 European Academy of Neurology.)
    • References:
      American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, DC: American Psychiatric Association, 2013.
      Scharf JM, Miller LL, Gauvin CA, et al. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord 2015; 30: 221-228.
      Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol 2012; 47: 77-90.
      Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res 2009; 67: 497-501.
      Freeman RD, Fast DK, Burd L, et al. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 2000; 42: 436-447.
      Mol Debes NM, Hjalgrim H, Skov L. Validation of the presence of comorbidities in a Danish clinical cohort of children with Tourette syndrome. J Child Neurol 2008; 23: 1017-1027.
      Pringsheim T, Lang A, Kurlan R, et al. Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009; 51: 468-472.
      Liu S, Zheng L, Zheng X, et al. The subjective quality of life in young people with Tourette syndrome in China. J Atten Disord 2017; 21: 426-432.
      Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019; 92: 896-906.
      Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019; 92: 907-915.
      Ganos C, Martino D, Pringsheim T. Tics in the pediatric population: pragmatic management. Mov Disord Clin Pract 2017; 4: 160-172.
      Yang C, Hao Z, Zhang LL, et al. Comparative efficacy and safety of antipsychotic drugs for tic disorders: a systematic review and Bayesian network meta-analysis. Pharmacopsychiatry 2019; 52: 07-15.
      Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. Eur Child Adolesc Psychiatry 2011; 20: 173-196.
      Neurological Group, Branch of Pediatrics, Chinese Medical Association. Expert consensus on diagnosis and treatment of tic disorder in children 2017. Chin J Appl Clin Pediatr 2017; 32: 1137-1140.
      Dale RC. Tics and Tourette: a clinical, pathophysiological and etiological review. Curr Opin Pediatr 2017; 29: 665-673.
      Ganos C. Tics and Tourette's: update on pathophysiology and tic control. Curr Opin Neurol 2016; 29: 513-518.
      Yael D, Vinner E, Bar-Gad I. Pathophysiology of tic disorders. Mov Disord 2015; 30: 1171-1178.
      Kataoka Y, Kalanithi PS, Grantz H, et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol 2010; 518: 277-291.
      Lennington JB, Coppola G, Kataoka-Sasaki Y, et al. Transcriptome analysis of the human striatum in Tourette syndrome. Biol Psychiatry 2016; 79: 372-382.
      Bouckenooghe T, Remacle C, Reusens B. Is taurine a functional nutrient? Curr Opin Clin Nutr Metab Care 2006; 9: 728-733.
      Ochoa-de la Paz LD, Martínez-Dávila IA, Miledi R, et al. Modulation of human GABAr1 receptors by taurine. Neurosci Res 2008; 61: 302-308.
      Ochoa-de la Paz LD, González-Andrade M, Pasantes-Morales H, et al. Differential modulation of human GABAC-ρ1 receptor by sulfur-containing compounds structurally related to taurine. BMC Neurosci 2018; 19: 47.
      Ochoa-de la Paz L, Zenteno E, Gulias-Cañizo R, Quiroz-Mercado H. Taurine and GABA neurotransmitter receptors, a relationship with therapeutic potential? Expert Rev Neurother 2019; 19: 289-291.
      Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28: 566-573.
      Guy W. Clinical Global Impressions (CGI) Scale, modified. In: Rush JA, eds. Handbook of Psychiatric Measures, 1st edn. Washington, DC: American Psychiatric Association, 2000.
      Ha CR, Kim SH, Na SB, You JS, Chang KJ. The association among dietary taurine intake, obesity and quality of sleep in Korean women. Adv Exp Med Biol 2015; 803: 725-773.
    • Grant Information:
      30971586 National Natural Science Foundation of China; 81371499 National Natural Science Foundation of China
    • Contributed Indexing:
      Keywords: taurine; tiapride; tic disorders; treatment outcome
    • Publication Date:
      Date Created: 20191017 Latest Revision: 20200210
    • Publication Date:
      20200827
    • Accession Number:
      10.1111/ene.14107
    • Accession Number:
      31618495
  • Citations
    • ABNT:
      DING, L. et al. Safety and efficacy of taurine as an add-on treatment for tics in youngsters. European journal of neurology, [s. l.], v. 27, n. 3, p. 490–497, 2020. DOI 10.1111/ene.14107. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=31618495. Acesso em: 26 out. 2020.
    • AMA:
      Ding L, Yang Z, Liu G, et al. Safety and efficacy of taurine as an add-on treatment for tics in youngsters. European journal of neurology. 2020;27(3):490-497. doi:10.1111/ene.14107
    • APA:
      Ding, L., Yang, Z., Liu, G., Ran, N., Yi, M., Li, H., Zhao, H., Tang, L., Cheng, H., Zhao, J., Zhang, Y., Ji, X., & Liu, S. (2020). Safety and efficacy of taurine as an add-on treatment for tics in youngsters. European Journal of Neurology, 27(3), 490–497. https://doi.org/10.1111/ene.14107
    • Chicago/Turabian: Author-Date:
      Ding, L, Z Yang, G Liu, N Ran, M Yi, H Li, H Zhao, et al. 2020. “Safety and Efficacy of Taurine as an Add-on Treatment for Tics in Youngsters.” European Journal of Neurology 27 (3): 490–97. doi:10.1111/ene.14107.
    • Harvard:
      Ding, L. et al. (2020) ‘Safety and efficacy of taurine as an add-on treatment for tics in youngsters’, European journal of neurology, 27(3), pp. 490–497. doi: 10.1111/ene.14107.
    • Harvard: Australian:
      Ding, L, Yang, Z, Liu, G, Ran, N, Yi, M, Li, H, Zhao, H, Tang, L, Cheng, H, Zhao, J, Zhang, Y, Ji, X & Liu, S 2020, ‘Safety and efficacy of taurine as an add-on treatment for tics in youngsters’, European journal of neurology, vol. 27, no. 3, pp. 490–497, viewed 26 October 2020, .
    • MLA:
      Ding, L., et al. “Safety and Efficacy of Taurine as an Add-on Treatment for Tics in Youngsters.” European Journal of Neurology, vol. 27, no. 3, Mar. 2020, pp. 490–497. EBSCOhost, doi:10.1111/ene.14107.
    • Chicago/Turabian: Humanities:
      Ding, L, Z Yang, G Liu, N Ran, M Yi, H Li, H Zhao, et al. “Safety and Efficacy of Taurine as an Add-on Treatment for Tics in Youngsters.” European Journal of Neurology 27, no. 3 (March 2020): 490–97. doi:10.1111/ene.14107.
    • Vancouver/ICMJE:
      Ding L, Yang Z, Liu G, Ran N, Yi M, Li H, et al. Safety and efficacy of taurine as an add-on treatment for tics in youngsters. European journal of neurology [Internet]. 2020 Mar [cited 2020 Oct 26];27(3):490–7. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=31618495